会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • 수두생바이러스백신용안정화제
    • VARICELLA-ZOSTER LIVE VIRUS VACCINE的稳定剂
    • KR1020000043714A
    • 2000-07-15
    • KR1019980060123
    • 1998-12-29
    • 한미사이언스 주식회사
    • 최재도신훈정성엽권세창이관순
    • A61K39/39
    • PURPOSE: A stabilizer for varicella-zoster live virus vaccine and attenuated varicella-zoster live virus vaccine containing the stabilizer are provided. The heat stability of the vaccine can be improved by adjusting the hydrolysis of gelatin in the stabilizer and the concentration of salt. CONSTITUTION: A manufacturing method of the stabilizer comprises the following steps: (a) 20-30 %(w/v) of gelatin is added in 0.1-1.5N HCl solution, hydrolyzed at 100-140°C for 70-110 minutes then neutralized; (b) the gelatin hydrolysate is added in phosphate buffer solution of pH7.2-7.6 which contains 0.01-0.03 %(w/v) of potassium chloride, 0.01-0.01 %(w/v) of potassium phosphate mono basic, 0.05-0.2 %(w/v) of sodium phosphate dibasic, 0.05-0.2 %(w/v) sodium glutamate and 5-10 %(w/v) of sucrose until the concentration of the gelatin becomes 1-3 %(w/v).
    • 目的:提供含有稳定剂的水痘带状疱疹活病毒疫苗和减毒水痘带状疱疹活病毒疫苗的稳定剂。 通过调节稳定剂中明胶的水解和盐的浓度可以提高疫苗的热稳定性。 构成:稳定剂的制造方法包括以下步骤:(a)将20-30%(w / v)明胶加入0.1-1.5N HCl溶液中,在100-140℃下水解70-110分钟,然后 中和; (b)将明胶水解产物加入pH7.2-7.6的磷酸盐缓冲溶液中,该溶液含有0.01-0.03%(w / v)的氯化钾,0.01-0.01%(w / v)的磷酸二氢钾, 0.2%(w / v)磷酸氢二钠,0.05-0.2%(w / v)谷氨酸钠和5-10%(w / v)蔗糖,直到明胶浓度变为1-3%(w / v )。
    • 5. 发明公开
    • 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
    • 人造粒菌群刺激因子变异及其生产方法
    • KR1020010009171A
    • 2001-02-05
    • KR1019990027418
    • 1999-07-08
    • 한미사이언스 주식회사
    • 권세창정성엽최기두김차순최재도이관순
    • C12N15/70C12N15/12
    • C07K14/535C07K2319/034C07K2319/75C12N15/625C12N15/70
    • PURPOSE: Provided are a human granulocyte-colony stimulating factor (hG-CSF) variant, a DNA encoding it, an expression vector comprising the DNA and a cell line transformed with the expression vector. The hG-CSF variant has high expression efficiencies, in case of expressing with a secretory sequence, it has an excellent secretion rate. Also, methionine free hG-CSF at its amino terminal or the variant thereof can be produced in large scale by secreting into periplasm . CONSTITUTION: The hG-CSF variant has one or more amino acids that is substituent of 1st, 2nd, 3rd and 17th amino acids of nature hG-CSF having an amino acid sequence of SEQ ID NO : 2 substituted, with other amino acids. Preferably, the variant has independently Thr1 and Cys17 substituted with Ser, Pro2 substituted with Met and Leu3 substituted with Val. The producing method of the hG-CSF variant comprises the steps of : transforming E. coli with an expression vector comprising a gene encoding hG-CSF or the variant thereof and a secretory sequence gene linked to 5'-end thereof; culturing the transformed E. coli under suitable condition to secrete the methionine free hG-CSF variant into the periplasm. The secretory sequence gene is E. coli-derived thermal-stable enterotoxin secretory sequence.
    • 目的:提供人粒细胞集落刺激因子(hG-CSF)变体,编码它的DNA,包含DNA和表达载体转化的细胞系的表达载体。 hG-CSF变体具有高表达效率,在用分泌序列表达的情况下,具有优异的分泌速率。 此外,其氨基末端的甲硫氨酸游离hG-CSF或其变体可以通过分泌到周质中而大量生产。 构成:hG-CSF变体具有一个或多个氨基酸,其是具有SEQ ID NO:2的氨基酸序列与其它氨基酸取代的天然hG-CSF的第1,第2,第3和第17氨基酸的取代基。 优选地,所述变体独立地被Ser1取代的Thr1和Cys17,被Met取代的Pro2和被Val取代的Leu3。 hG-CSF变体的制备方法包括以下步骤:用包含编码hG-CSF或其变体的基因的表达载体和与其5'末端连接的分泌序列基因转化大肠杆菌; 在合适的条件下培养转化的大肠杆菌以将无甲硫氨酸的hG-CSF变体分泌到周质中。 分泌序列基因是大肠杆菌来源的热稳定肠毒素分泌序列。